FINWIRES · TerminalLIVE
FINWIRES

研究快讯:Macerich公司第一季度:以2.72亿美元收购Annapolis公司将增强其未来投资组合。

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:MAC第一季度营收为2.42亿美元,同比下降3.1%,环比下降7.8%,其中租赁收入为2.26亿美元。按比例计入未并表合资企业的收入为2.97亿美元,同比下降3.0%。该公司的SNO项目储备达到1.16亿美元,代表到2028年累计新增收入,我们认为这将是未来增长势头的积极催化剂。MAC将以“未来投资组合中心”指标取代同店净营业收入(NOI)报告。 未来投资组合净营业收入(不计租赁终止收入)同比增长1.2%至1.73亿美元,而投资组合租户每平方英尺销售额在过去12个月达到899美元,同比增长7.4%,较2025年第四季度增长2.0%。未来投资组合中心每平方英尺销售额达到941美元,同比增长4.8%,较2025年第四季度增长2.2%。MAC在第一季度签署了160万平方英尺的租赁合同,同比增长2.5%(不计上年同期多地点主力店续租)。我们认为,尽管收入环比下降,但销售效率的提高和强劲的租赁势头将支撑公司的运营进展。

Related Articles

Asia

StarHub's Net Attributable Profit Falls 81% in Q1

StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.

$SGX:CC3
Asia

Meesho Narrows Consolidated Loss in Fiscal Q4

Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.

$BOM:544632$NSE:MEESHO
Asia

Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug

Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.

$SHE:000661